Hidden Fee Disclosure Act of 2025
- Bill Number
- H.R. 2041
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Labor and Employment
- Status
- Introduced
- Latest Action
- 2025-03-11: Referred to the House Committee on Education and Workforce.
- Last Updated
- 2026-04-13T17:56:55Z
AI-Generated Summary
Purpose
The Hidden Fee Disclosure Act of 2025 aims to increase transparency in employer-sponsored health plans by amending the Employee Retirement Income Security Act of 1974 (ERISA). It targets "hidden fees" charged by service providers, such as pharmacy benefit managers (PBMs) and third-party administrators (TPAs), to help plan sponsors and fiduciaries better evaluate costs, compensation, and potential conflicts of interest.
Key Provisions
- Expansion of Covered Services: Broadens the list of services requiring fee disclosures under ERISA, including plan design, claim repricing, insurance selection (e.g., vision and dental), recordkeeping, medical management, benefits administration, stop-loss insurance, pharmacy benefit management, wellness programs, transparency tools, group purchasing, disease management, compliance services, employee assistance programs, and related consulting.
- Clarified Disclosure Rules: Requires service providers to disclose compensation details by service (not just in aggregate), covering direct and indirect payments like fees, rebates, discounts, and other remuneration.
- Specific Requirements for PBMs:
- Treats certain PBM contracts (including those involving health insurance issuers) as "indirect" arrangements, subjecting them to ERISA's fiduciary conflict rules (which prohibit self-dealing).
- Mandates initial disclosures of all expected compensation from drug makers, distributors, pharmacies, and others, including rebates, spread pricing (paying pharmacies less than charged to the plan), and fees for data access or rebate handling.
- Requires annual disclosures (within 60 days of each plan year start) on prior-year spending (gross and net on drugs), pharmacy-owned costs, excess cost-sharing collections, and total fees by source.
- Defines PBM services to include claims processing, network design, rebate negotiation, formulary management, pharmacy operations, utilization review, and more.
- Specific Requirements for TPAs:
- Initial disclosures of rebates, discounts, and fees from providers/facilities (including retained amounts), plus expected recoveries from overpayments, errors, subrogation (recovering costs from third parties), fraud, etc.
- Annual disclosures on compensation, gross/net spending under administrative agreements, aggregate fees, and cost-sharing impacts.
- Defines TPA services for group health plans to include claims processing/repricing, provider network management, discount negotiation, benefit design, recordkeeping, utilization review, compliance, and similar tasks.
- Privacy Protections: Disclosures must comply with HIPAA (Health Insurance Portability and Accountability Act) privacy rules, limiting use to summary health information (non-identifiable data). Recipients (e.g., plan fiduciaries) can only share with the plan, the provider, or HIPAA-defined business associates. Public disclosure is restricted, except to the Department of Labor (DOL), and does not alter existing protected health information rules.
- Implementation and Effective Date: DOL must issue regulations within one year of enactment, accounting for varied compensation practices and setting disclosure standards. Changes apply to contracts entered or renewed on/after January 1, 2026; pre-2026 contracts are exempt unless renewed.
Significant Changes to Existing Law
- Broader Scope: Expands ERISA's Section 408(b)(2) to explicitly include more health plan services and treat PBM arrangements as indirect (potentially triggering stricter fiduciary oversight under ERISA Section 406(a)(1)(C), which bans certain conflicts).
- Detailed and Annual Reporting: Shifts from general to service-specific disclosures; adds mandatory annual reports for PBMs and TPAs with granular data (e.g., on rebates, spread pricing, recoveries) not previously required.
- New Definitions and Privacy Integration: Introduces definitions for PBM and TPA services; incorporates HIPAA privacy standards directly into ERISA disclosures, ensuring de-identified data and limiting redisclosure.
- No Retroactivity Implication: Clarifies that new disclosure requirements do not imply prior practices were legal, maintaining enforcement against existing violations.
Potential Impacts
- On Citizens (Employees and Beneficiaries): Greater transparency into drug and health plan costs could lead to lower out-of-pocket expenses, better-informed choices, and reduced "hidden" fees that inflate premiums or copays.
- On Government Agencies: DOL gains rulemaking and oversight responsibilities to enforce disclosures, potentially increasing administrative workload but improving ERISA compliance monitoring. No direct impact on international relations.
- On Employers and Plans: Plan sponsors (e.g., companies) receive more data to assess service provider reasonableness and conflicts, aiding fiduciary decisions but adding review burdens.
- On Service Providers: PBMs, TPAs, insurers, and affiliates face heightened compliance costs for detailed reporting, which may discourage opaque practices like spread pricing or rebate retention.
Main Stakeholders Affected
- Employer-Sponsored Health Plans and Fiduciaries: Primary beneficiaries of disclosures, responsible for reviewing and acting on reported data.
- Covered Service Providers: PBMs, TPAs, health insurers, pharmacies, drug manufacturers, and consultants must provide detailed, timely information.
- Employees and Beneficiaries: Indirectly benefit from potential cost savings and transparency in benefits administration.
- Department of Labor: Oversees implementation, rulemaking, and enforcement.
- Health Industry Entities: Including drug distributors, group purchasing organizations, and wellness providers, due to expanded service coverage.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens ERISA fiduciary duties by enhancing transparency, potentially increasing litigation risk for non-compliant providers (e.g., under prohibited transaction rules). Aligns with HIPAA without altering its core protections, avoiding conflicts in health data handling. The rule of construction preserves DOL's ability to deem undisclosed practices illegal.
- Constitutional: No apparent issues; amendments operate within Congress's commerce clause authority over employee benefits and interstate health markets.
- Political: Promotes accountability in healthcare costs, a bipartisan concern (introduced by representatives from both parties), but may face industry pushback over compliance burdens. Could influence broader debates on drug pricing and plan affordability without mandating fee reductions.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2025-03-11: Referred to the House Committee on Education and Workforce.
- 2025-03-11: Introduced in House
- 2025-03-11: Introduced in House
Bill Versions
- Hidden Fee Disclosure Act of 2025 — issued 2025-03-11 — PDF (19 pages)